BEYOND INFORMED CONSENT: FACILITATING INNOVATION IN A JUST WORLD

PROF. LEONARDO D. DE CASTRO Chair Philippine Health Research Ethics Board

Centre for Biomedical Ethics YLL School of Medicine NATIONAL UNIVERSITY OF SINGAPORE

INFORMED CONSENT PARADIGM FOR RESEARCH ETHICS

Informed by experience with Nazi Experimentation on Human Beings Exploitation of vulnerable subjects Human Beings as mere instruments No consent No concern for subjects' interests or safety No benefits Non-medical over medical purposes



CONTINUING RELEVANCE OF INFORMED CONSENT

- Uneven relationship between investigator and research
- Risks inherent to experimentation
- Injustices abound
 - Use of subjects who can never benefit from findings
 Excessive recruitment of the economically challenged
 Inequitable access to benefits



CONTINUING RELEVANCE OF INFORMED CONSENT

- In international research, subjects' distance from conceptualizers of research is magnified.
 - Lack opportunity for timely and weighty feedback
 - Inadequate understanding of research
 - Failure to appreciate subjects' interests



HOW PATIENTS (COULD?) BECOME SUBJECTS

- Having tissues/samples taken for diagnostic examination
- Participating in non-genetic research that requires tissues to be drawn and stored
 Submitting oneself for genetic testing
 Undergoing In Vitro Fertilization
 Having a genetic relative participate in research in any of the above ways



HOW PATIENTS (COULD?) BECOME SUBJECTS

Having one's records kept in a hospital
Being the recipients of aid after a disaster
Being a patient in an emergency situation



ISSUES WITH PREVAILING INFORMED CONSENT PARADIGM

- Ethical requirements of consent for all future uses cannot be satisfied at the time a potential research subject is engaged.
- Tissue Providers (TPs) have generally expressed willingness to contribute to research with only minimal information about a study

Puts a great deal of responsibility on the TP
To make a decision at the outset
To give up control over donated material at the time consent is taken



Studies about Informed Consent



decastro BEYOND INFORMED CONSENT 08242015

Study in Vasterbotten, Sweden:

Hoeyer et al:

Informed consent and biobanks: a populationbased study of attitudes towards tissue donation for genetic research General acceptance of genetic research based on biobank material (71%)
 Majority (62%) would not allow researchers to examine their healthcare records without specific consent.



Study in Vasterbotten, Sweden:

Majority (66.8%) accepted surrogate decisions by research ethical committees; ♣ 48% would feel respected if they were notified each time a sample was used.

Re future health risks, a majority (55%) would want to be told only if treatment was available
 Informed consent was a principal concern to a minority (4%) only.



Consent to use of Residual Tissue among Cancer Patients in the Netherlands

Vermeulen et al:

"Obtaining 'fresh' consent for genetic research with biological samples archived 10 years ago" One-time general consent' was considered to be the best procedure for consenting to research with stored tissue by 56%,

- 4 23% favoured the current 'optout' procedure;
- 4 21% did not know or had no preference.



Willingness to donate blood samples for genetic research: community sampling

49.3% (95% CI, 45.1–53.5%) were willing to donate blood for genetic research
willingness was significantly associated with:
belief in the benefits
intention to participate in government studies;
having no fear of pain, blood, injections, and needles; and
non-concern about the loss of confidentiality
Wong, et al. Clinical Genetics, Volume 65, Number 1, January 2004, pp. 45-51(7)



Wendler Metadata: One-time General Consent

(79-95%) willing to provide one-time general consent and rely on ethics committees to determine the studies for which their samples would be used.

Even research on potentially stigmatising conditions

David Wendler BMJ 2006;332:544-547



decastro BEYOND INFORMED CONSENT 08242015

Wendler Metadata: One-time General Consent

Three studies: people marginally less willing to provide a sample for commercial rather than academic research.

A Nine studies: like some information on the projects for which their samples will be used, although the type of information desired was not specified.

David Wendler BMJ 2006;332:544-547



Wendler Metadata: One-time General Consent

Ethics committees to determine that future projects are acceptable and pose no more than minimal risks

Increases scientific and social value of donated samples

Lowers costs of conducting research by eliminating the need to track the choices for each sample.
Minimizes inconvenience of being repeatedly contacted and asked for consent



Matsui, "The Ethics of Non-Specific Consent to Unforeseen Uses of Biobanked Materials: Donors' Views and Rationales" (2012)

Table 3.	Consent ra	ites to th	e sharing	of donated	samples/data
----------	------------	------------	-----------	------------	--------------

Consent items	All donors (N = 336)	Male (N = 138)	Female (N = 198)
	Number (%)	Number (%)	Number (%)
Allowing my data to be provided to the <i>Tougoukenkyu</i> of the JALS ^a	322 (95.8)	132 (95.7)	190 (96.0)
Allowing my samples/data to be provided to the J-MICC Study ^b	162 (95.3)	55 (96.5)	107 (94.7)
Allowing my samples/data to be provided to various unspecified future (collaborative) research	291 (86.6)	122 (88.4)	169 (85.4)

Abbreviations: JALS, Japan Arteriosclerosis Longitudinal Study; J-MICC Study, Japan Multi-Institutional Collaborative Cohort Study.

Matsui, "The Ethics of Non-Specific Consent to Unforeseen Uses of Biobanked Materials: Donors' Views and Rationales" (2012)

Re-consent conditions	All consenters to unspecified future research (n = 289) ^a		Female (n = 169)
	Number (%)	Number (%)	Number (%)
No need to re-obtain my (or my family's) consent at a new research proposal provided that the institutional research ethics committee approves it	223 (77.2)	92 (76.7)	131 (77.5)
Need to re-obtain my (or my family's) consent at every new research proposal in addition to the approval by the institutional research ethics committee	64 (22.1)	28 (23.3)	36 (21.3)
N/A	2 (0.7)	0 (0.0)	2 (1.2)

* Two male subjects who chose both conditions at the same time were excluded.

DELIBERATIVE APPROACH

Secko et al:

Informed consent in biobank research: a deliberative approach to the debate Strong support for biobanks General reduction in concern for withdrawal of samples Need for review of biobanks research that is independent of funders and researchers. Persistent disagreement about when consent was required for new

research activities

Can open consent be 'informed'

Hallinan & Friedewald: Open consent, biobanking and data protection law: can open consent be 'informed' under the forthcoming data protection regulation? 2014

Open consent cannot meet information requirements with adequate specificity: Purpose, Recipient, Possible third country transfers, Data collected Applicable consent requirements should be rethought



Can open consent be 'informed'

Hallinan & Friedewald: Open consent, biobanking and data protection law: can open consent be 'informed' under the forthcoming data protection regulation? 2014 Open consent in biobanking does not present great risk to subject
 There are grounds for a reconsideration of consent

requirements

Provide legal protection against the harms that could come through the use of data by third parties

Protection can be provided outside the research process

Informed Consent and Comprehension

Beskow et al:

Informed consent for biobanking: consensus-based guidelines for adequate comprehension Consensus (>70% agreement) concerning what specific details participants should know about 16 biobank consent topics.

Achieved for 15 of the 16 consent topics.

Exception: comprehension needed regarding the Genetic Information Nondiscrimination Act



Informed Consent and Comprehension: Recommendations

Improve consent forms:

Beskow et al:

Informed consent for biobanking: consensus-based guidelines for adequate comprehension

Focus on information most important to prospective participants.



Informed Consent and Comprehension: Recommendations

Improve consent processes:

Beskow et al:

Informed consent for biobanking: consensus-based guidelines for adequate comprehension

Focus on effectively communicating the most crucial information



Informed Consent and Comprehension: Recommendations

Beskow et al:

Informed consent for biobanking: consensus-based guidelines for adequate comprehension

Facilitate research on biobanking consent



	Adequate comprehension?" n (%)		
		Disagree	
Consent form topic	Agree	Too little	Too much
Biobank purpose: "The purpose of this project is to collect and store samples and health information for use in future research."	41 (87)	6(13)	0 (0)
Blood draw: "You are going to draw blood from me."	35 (74):	12 (26)	0 (0)
Collection of information: "You will ask me some basic information and will contact me to update this information. You will also collect information from my medical records."	46 (98)	1 (2)	0 (0)
Duration of storage: "My sample and information will be stored forever unless I decide to stop taking part."	46 (98):	0 (0)	1 (2)
Access to biospecimens/data: "Researchers may study my samples and information. You will not give researchers information that could identify me."	35 (74):	11 (23)	1 (2)
Recontact: "Someone from the biobank may contact me about participating in additional research."	41 (87)	5(11)	1 (2)
Large-scale data sharing: "Some of my information might be put into a database. There is a small chance that someone could trace my information back to me."	39 (83):	5(11)	3 (6)
Risks: "There is a risk that someone could get access to information about me."	33 (70)*	11 (23)	3 (6)
Confidentiality protections: "You will take many steps to protect my privacy."	43 (91)	2 (4)	2 (4)
Genetic Information Nondiscrimination Act: "There is a law against discrimination based on my information."	28 (60)	12 (26)	7 (15)
Alternate: There is nothing in this section a prospective participant must understand to give valid consent.	25 (53)	NA	NA
Certificate of confidentiality: There is nothing in this section a prospective participant must understand to give valid consent.	36 (77) ^c	NA	NA
Potential benefits: "I should not expect to benefit from this research."	45 (96) ^c	1 (2)	1 (2)
Costs and payments (commercialization): "I will not get money from anything that is done using my sample."	43 (91) [:]	3 (6)	0 (0)
Return of results: "I should not expect to get individual results back from this research."	40 (85) ^c	6 (13)	0 (0)
Discontinuing participation: "I have the right to leave the project. However, I cannot withdraw or get back samples and information from studies that have already begun."	41 (87) ^c	2 (4)	4 (9)
Questions or problems: "There is someone I can contact if I have questions or want more information."	46 (98):	0 (0)	0 (0)

*Agreed or strongly agreed on a four-point scale in response to "How much do you agree or disagree that the statement above generally represents adequate comprehension of the consent topic?" *Among those who disagreed or strongly disagreed that the statement represents adequate comprehension, responses to question about whether the statement reflects more or less than a prospective participant needs to understand to provide valid consent. (Reached consensus, predefined as >70% agreement.)

decastro BEYOND INFORMED CONSENT 08242015

CONSENT FORM TOPICS

DONATION AS AN OPTION

Views of subject donors regarding donation of samples: 85.3 – 98.5% (England, France, India, Japan, Singapore, Sweden, Uganda, UK & US) Positive Views of public non-donors: De Costa, 2004: 59 Indians – 86% ■ Wong, 2004: 708 Singaporeans – 49.3% Ashcroft, 2003: 155 UK – 100% Schwartz, 2001: 1383 Jewish Americans - >80% ■ Wang, 2001: 3130 US – 79% Mertz, 1996: 99 US – 60%



Prevailing Consent Paradigm:

Fails to reflect preferences of research participants
 Puts unnecessarily heavy burden on participants to protect their interests
 Indicates a need for governance model adapted to variable research conditions and information requirements.



DYNAMIC CONSENT

Informed about broad range and foreseeable details of potential uses

Withdrawal of consent at any time for any reason (or even no reason) without adverse repercussions

Potential donors' option of not having to reconsent in future if they so choose



Dynamic Consent

Subject-stipulated exceptions and options
 Clear protocol for withdrawal
 Reasonable deadline
 Clarity about what happens to information after withdrawal



DYNAMIC CONSENT

Allows for individuals to be informed about or counseled on what is at stake, up to the level at which they feel their autonomy has been respected



Dynamic Consent: Option to Keep Informed

- Accepts the need to update the list of potential uses periodically, seeks to inform donors of the updated list
 Mechanism for donors to keep informed about developments with respect to research materials if they want to
- Accessible website or regular newsletters that contributors can either read or ignore



Dynamic Consent

Co-guardianship of the donated samples with a research ethics board or an oversight body on specific uses of the donated material.
 Ethics Committee approval for each use
 Continuing Ethics Committee Oversight



Institutional Accountability

Accreditation of research institutions
 Institutionally based Researchers and ECs
 Requirement for local institutional affiliation of researchers



Legal Framework

Export and import of materials
 Materials Transfer Agreements
 Local institutional participation in foreign-sponsored research



Transparency

 Registration/ Publication of research and research outcomes
 Availability of updated information on use of HBMs



More Recommendations

Involve civil society representatives in ethics review
 Public consultation regarding population genetics research

Raise general public's level of awareness



TIME TO SHIFT FOCUS?

FROM CLOSED CONSENT

TO DYNAMIC CONSENT



decastro BEYOND INFORMED CONSENT 08242015

INNOVATION: FREEDOM OF RESEARCH

 FREEDOM OF THOUGHT
 RESPONSIBILITY TO EXPLORE HUMAN POTENTIAL
 RESPONSIBILITY OF ALL HUMAN BEINGS



INNOVATION FOR WHAT?

WHERE ARE WE GOING?

A sense of where we are
A sense of where we want to be
A SENSE OF PURPOSE









INNOVATION FOR WHOM?

Relevance to the weak and vulnerable

Access to benefits by the research population
 Access to benefits by the poor and vulnerable



INNOVATIVE RESEARCH

INNOVATIVE ETHICS REVIEW



decastro BEYOND INFORMED CONSENT 08242015

A SHIFT OF FOCUS

FROM ETHICS (P)REVIEW

TO ETHICS OVERSIGHT

DYNAMIC CONSENT



decastro BEYOND INFORMED CONSENT 08242015